Division of Digestive and Liver Diseases, Columbia University Irving Medical Center, 630 West 168th Street, 3rd Floor, New York, NY, 10032, USA.
College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Dig Dis Sci. 2022 Sep;67(9):4484-4491. doi: 10.1007/s10620-021-07324-4. Epub 2021 Nov 24.
Patients with SARS-CoV-2 who present with gastrointestinal symptoms have a milder clinical course than those who do not. Risk factors for severe COVID-19 disease include increased adiposity and sarcopenia.
To determine whether body composition risk factors are associated with worse outcomes among patients with gastrointestinal symptoms.
This was a retrospective study of hospitalized patients with COVID-19 who underwent abdominal CT scan for clinical indications. Abdominal body composition measures including skeletal muscle index (SMI), intramuscular adipose tissue index (IMATI), visceral adipose tissue index (VATI), subcutaneous adipose tissue index (SATI), visceral-to-subcutaneous adipose tissue ratio (VAT/SAT ratio), and liver and spleen attenuation were collected. The association between body composition measurements and 30-day mortality was evaluated in patients with and without gastrointestinal symptoms at the time of positive SARS-CoV-2 test.
Abdominal CT scans of 190 patients with COVID-19 were evaluated. Gastrointestinal symptoms including nausea, vomiting, diarrhea, or abdominal pain were present in 117 (62%). Among patients without gastrointestinal symptoms, those who died had greater IMATI (p = 0.049), less SMI (p = 0.010), and a trend toward a greater VAT/SAT ratio. Among patients with gastrointestinal symptoms, those who died had significantly greater IMATI (p = 0.025) but no differences in other measures.
Among patients with COVID-19, those without gastrointestinal symptoms showed the expected associations between mortality and low SMI, high IMATI, and trend toward higher VAT/SAT ratio, but those with gastrointestinal symptoms did not. Future studies should explore the mechanisms for the altered disease course in patients with COVID-19 who present with gastrointestinal symptoms.
与没有胃肠道症状的患者相比,出现胃肠道症状的 SARS-CoV-2 患者的临床病程较轻。COVID-19 重症的危险因素包括肥胖和肌肉减少症。
确定胃肠道症状患者的身体成分危险因素是否与不良结局相关。
这是一项回顾性研究,纳入因临床指征行腹部 CT 扫描的 COVID-19 住院患者。收集包括骨骼肌指数(SMI)、肌内脂肪组织指数(IMATI)、内脏脂肪组织指数(VATI)、皮下脂肪组织指数(SATI)、内脏与皮下脂肪组织比(VAT/SAT 比)、肝脏和脾脏衰减在内的腹部身体成分指标。在 SARS-CoV-2 检测阳性时伴有或不伴有胃肠道症状的患者中,评估身体成分测量值与 30 天死亡率之间的关系。
共评估了 190 例 COVID-19 患者的腹部 CT 扫描。117 例(62%)患者出现胃肠道症状,包括恶心、呕吐、腹泻或腹痛。在无胃肠道症状的患者中,死亡患者的 IMATI 更大(p=0.049),SMI 更小(p=0.010),且 VAT/SAT 比呈增大趋势。在有胃肠道症状的患者中,死亡患者的 IMATI 明显更大(p=0.025),但其他指标无差异。
在 COVID-19 患者中,无胃肠道症状的患者死亡率与低 SMI、高 IMATI 和 VAT/SAT 比增大的预期关联,但有胃肠道症状的患者则没有。未来的研究应探讨 COVID-19 患者出现胃肠道症状时疾病病程改变的机制。